NephroQuiz: a fishy rash.

NephroQuiz is curated by BMC Nephrology Editorial Board Members from Johns Hopkins University, Dr. Hanouneh and Dr. Cervantes. It aims to engage readers with clinical vignettes and problem solving. The USMLE-style questions are designed to test knowledge and engage with published literature.
NephroQuiz: a fishy rash.
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

A 51-year-old man presented for evaluation of a newly developed rash (xerosis with hyperpigmented scaly lesions on his arms, legs, abdomen, and back). Skin biopsy showed hyperkeratosis with non-necrotising granulomas. He had no medical history, did not report any nausea, vomiting, chest pain, dyspnea, or urinary symptoms. On examination his blood pressure was 125/75 mmHg, pulse rate was 85 beats per minute, and his oxygen saturation was 96%.  

Laboratory investigations showed creatinine 6.27 mg/dL (normal range 0.67–1.17; a baseline measurement 2 months before he presented was 0.9), sodium 137 mmol/L (normal range 136–145), potassium 3.8 mmol/L (normal range 3.5–5.1), bicarbonate 22 mmol/L (normal range 22–29), calcium 15.1 mg/dL (normal range 8.6–10.2), albumin 4.3 g/dL (normal range 3.5–5.2), ionized calcium 1.91 mmol/L (normal range 1.17–1.38), parathyroid hormone (PTH) 9.1 pg/mL (normal range 18.4–80.1), PTH-related protein 3.4 pmol/L (normal range 0.0–2.3), 1,25-dihydroxyvitamin D 97.3 pg/mL (normal range 19.9–79.3), and angiotensin-converting enzyme 120 U/L (normal range 16–85).

Urinalysis was positive for proteinuria with a urine protein-to-creatinine ratio of 0.92. Further serology workup showed the following: negative hepatitis B virus, hepatitis C virus, and HIV serologies, normal C3 and C4, undetectable antinuclear antibodies (ANAs), anti-double stranded DNA antibodies titer of <1:10 (normal <1:10), negative antineutrophil cytoplasmic antibodies (ANCAs), serine protease 3 antibodies (PR3-ANCAs) titer of 0 AU/mL (normal 0–19), myeloperoxidase antibodies (MPO) titer of 0 AU/mL (normal 0–19), and phospholipase A2 receptor (PLA2R) antibody titer of <1:10 (normal <1:10).

Kidney biopsy (shown above) was performed with: light microscopy hematoxylin and eosin stain (A), light microscopy periodic acid methenamine silver stain (B), IgG Immunofluorescence microscopy (C), electron microscopy (D). 

The correct answer and explanation will be revealed once you select an answer in the multiple choice question above. 

Click here to read the original case report. We encourage discussion of the case and questions in the comments. 

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Nephrology
Life Sciences > Health Sciences > Clinical Medicine > Nephrology
  • BMC Nephrology BMC Nephrology

    This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.

Related Collections

With Collections, you can get published faster and increase your visibility.

Risk stratification through AI application in kidney care

The increasing global burden of chronic kidney disease (CKD) necessitates an ongoing exploration of innovative strategies to enhance patient management and optimise healthcare delivery. Artificial Intelligence (AI) offers unprecedented opportunities for risk stratification in kidney care, harnessing vast datasets to inform clinical decision-making, improve patient outcomes, and drive efficiencies in healthcare systems.

AI-based CKD progression prediction models leverage machine learning algorithms to analyse patient data, enabling healthcare professionals to identify individuals at heightened risk of disease progression. These tools have been validated in various clinical settings and demonstrate considerable potential in personalising patient care.

Machine learning risk scoring for dialysis initiation has emerged as a vital resource, improving decision-making processes by facilitating timely interventions. Predictive analytics for transplant eligibility ensure that patients receive the most suitable and timely interventions based on their unique health profiles. This algorithmic stratification of renal patient cohorts allows for a more nuanced understanding of patient needs, moving us beyond a one-size-fits-all approach to a model that emphasises individualised care.

The potential of AI in risk stratification encompasses the broad spectrum of healthcare delivery, influencing policy formulation, resource allocation, and patient education. By continuing to expand our collective understanding in this area, we can foster an environment where AI-driven innovations are systematically integrated into kidney care protocols.

Topics of interest include but are not limited to:

  • AI-based CKD progression prediction
  • Machine learning risk scoring for dialysis initiation
  • Predictive analytics for transplant eligibility
  • Algorithmic stratification of renal patient cohorts
  • Personalised nephrology risk models
  • Integration of social determinants in risk assessment
  • Impact of AI on patient engagement and outcomes
  • Interoperability challenges and solutions in kidney care

We welcome submissions employing AI and Machine Learning approaches, as well prediction models that use regression or machine learning methods. We recommend adhering to TRIPOD guidelines for reporting clinical prediction models that use regression or machine learning methods.

We encourage authors to share accompanying data. According to our policies, submission of a manuscript to a BMC journal implies that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality. We require data deposition for some data types. Further information can be found in our policies.

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

Publishing Model: Open Access

Deadline: Mar 19, 2027

Mental health integration in nephrology

The intersection of mental health and nephrology is gaining increasing recognition as a critical component of integrated patient care. Chronic kidney disease (CKD), along with treatments such as dialysis and kidney transplantation, is frequently associated with significant psychological distress, leading to poorer health outcomes. This Collection aims to explore the integration of mental health support within nephrology practices, addressing how psychological factors influence disease management and patient quality of life.

Recent advances in this field include the implementation of routine depression screening in dialysis settings and the development of integrated behavioral health models within nephrology clinics. These strategies have shown promise in addressing the psychological needs of patients and their family caregivers, fostering better adherence to treatment regimens, and ultimately improving physical and mental well-being among this population.

We welcome submissions including original research, reviews, and implementation studies. Topics of interest include, but are not limited to:

  • Psychological support in CKD
  • Depression screening in dialysis and transplant patients
  • Integrated behavioral health in nephrology care
  • Cognitive and behavioral interventions in CKD management
  • Digital mental health interventions in nephrology
  • Dyadic and family-based interventions in CKD management

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

Publishing Model: Open Access

Deadline: Jan 30, 2027